Effect of Discontinuing Prophylaxis with Norfloxacin in Patients with Hematologic Malignancies and Severe Neutropenia

Rodrigo Martino(Universitat Autònoma de Barcelona), S Brunet(Hospital San Juan de la Cruz), Albert Altés(Hospital de Sant Pau), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), R. Pericás(Hospital de Sant Pau), R.A. Medina López(Clínica Santa María), A Domingo-Albós(Clínica Rementería), Maricel Subirá(Hospital de Sant Pau)
Acta Haematologica
January 1, 1998
10.1159/000040840
Cited by 39

Related Papers

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2015|740
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2022|718
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
|New England Journal of Medicine|2023|538
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532